Quick Facts

• Primary Therapeutic Area: Management of Cystic Fibrosis (CF).
• Objective: Used to promote the clearing of mucus from the lungs.
• Key Benefit: Helps to support pulmonary function in adult and pediatric patients.
• Additional Benefit: May assist in reducing the likelihood of respiratory infections that require injectable antibiotics in select patient populations.

---

Пульмозим (dornase alfa) is a prescription inhalation solution utilized as a component of the comprehensive management plan for patients with cystic fibrosis (CF). Its primary role is to provide assistance in the management of thick, sticky secretions within the respiratory tract, which are characteristic of CF.

Use of this medication is indicated in conjunction with other established therapies for CF. By supporting the clearance of secretions, Пульмозим helps to maintain and potentially support an improvement in overall pulmonary function in both adult and pediatric patients. For certain patients who meet specific pulmonary function criteria, the medication may contribute to a reduction in the risk of respiratory tract infections that require antibiotic administration via injection.

Who can and cannot use Пульмозим (Dornase Alfa) — Official Regulatory Information

Official regulatory documents define the eligible patient population for Dornase alfa based on the presence of cystic fibrosis, age, and specific exclusionary criteria.

---

Contraindications and Exclusionary Groups

The medicine is absolutely contraindicated in patients with a known hypersensitivity to the active ingredient, dornase alfa. This prohibition also extends to patients with hypersensitivity to Chinese Hamster Ovary (CHO) cell products or any other component of the formulation.

Age-Related Eligibility

The medicine is indicated for pediatric and adult patients with cystic fibrosis (CF).

• Pediatric Use: Safety and effectiveness have been established in patients 5 to 17 years of age. Efficacy data is extrapolated to children as young as 3 months of age, supported by additional safety data.
• Geriatric Use: No geriatric-specific problems have been documented to date, though specific studies have not been performed in this older population.

Conditional Use and Special Populations

Category	Official Regulatory Status
Pulmonary Function	For CF patients with a Forced Vital Capacity (FVC) ge 40% of predicted, use has been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.
Pregnancy	Safety has not been established in pregnant women; use requires caution.
Lactation	Caution is recommended during breastfeeding as it is unknown whether the substance is excreted in human milk.

Interaction Map: Interactions with other medicines and products — official regulatory information for Dornase alfa

The official regulatory profile for Dornase alfa is primarily defined by its physical incompatibility and documented compatibility with core Cystic Fibrosis (CF) treatments, reflecting its localized pulmonary delivery.

Specific Interacting Medicines

• Prohibition: The only specific interaction restriction is with any other medicinal product if co-administered in the nebulizer.
• Compatibility: Official documents state that Dornase alfa can be safely used with categories of medicines commonly administered to patients with CF, including antibiotics (oral, inhaled, and parenteral), bronchodilators, pancreatic enzyme supplements, inhaled and systemic corticosteroids, vitamins, and analgesics.

Mechanistic Basis and Restriction

The primary documented constraint is based on the risk of adverse physicochemical and/or functional changes that may occur in Dornase alfa or the admixed compound if dilution or mixing occurs in the nebulizer device. Therefore, a mandatory administration restriction applies: Dornase alfa must not be diluted or mixed with any other solution in the nebulizer cup.

Systemic and Substance Interactions

There are no systemic pharmacokinetic interactions (CYP enzyme or transporter-mediated) documented in the regulatory labeling due to the drug's minimal systemic absorption. Furthermore, official labeling does not document clinically relevant interactions with food, alcohol, or herbal products.

Connection to the overall interaction profile

The interaction structure confirms that Dornase alfa is suitable for use alongside necessary concurrent treatments for CF. The required separation of administration is strictly procedural, focused on maintaining the integrity of the solution, which prevents the co-administration of Dornase alfa with any other product in the same nebulization session. This profile contains no officially documented warnings regarding systemic metabolic or exposure-altering interactions.

Targeted Enzymatic Breakdown of Extracellular DNA

Dornase alfa functions as a recombinant human deoxyribonuclease I (rhDNase), an enzyme that specifically targets and cleaves the long polymeric strands of extracellular DNA (eDNA). This eDNA, released from dead neutrophils in purulent secretions, is dismantled via endonucleolytic cleavage, breaking it down into smaller oligonucleotide fragments.

---

Modulation of Sputum Viscoelasticity

The primary functional consequence of eDNA breakdown is the modulation of sputum rheology. By eliminating the eDNA—a major structural component that provides the gel-like consistency—the drug reduces the viscosity (thickness) and elasticity (stickiness) of the secretions. This change converts the highly tenacious material into a state of reduced viscosity, which lowers the internal mechanical resistance.

---

️ Facilitation of Physiological Airway Clearance

This mechanistic cascade directly influences the respiratory system’s natural clearance processes. The resultant reduction in adhesiveness and required mobilization force facilitates the function of the mucociliary escalator and the cough mechanism on the accumulated material within the airways. This action influences the physical properties of the pulmonary secretions that interact with the respiratory tract.

Instruction Map: How to use Пульмозим — Administration Guidelines

Administration Scope

The administration of Dornase alfa is limited to inhalation as an aerosol mist, requiring the use of a specific, approved jet nebulizer or vibrating mesh nebulizer system. The standard dose is 2.5 mg, which is the complete content of one single-use ampule. This dosing is typically scheduled for once daily use, though a twice-daily regimen may be utilized in certain patients who benefit from the higher frequency. The solution is administered undiluted, and is not to be mixed with any other medications or diluents in the nebulizer chamber. The ampule's contents should be visually inspected and should be clear and colorless prior to use.

Age-Group and Procedural Rules

The 2.5 mg once-daily dose is the established regimen for both adult and pediatric patients starting at 3 months of age. Treatment is intended to be a continuous, long-term daily protocol. If an administration is missed, the next scheduled dose is continued at the usual time; doubling the next administration to compensate is advised against.

Step Sequence

The sequence for use involves:

• Visually inspect the solution and discard the ampule if the contents are cloudy or discolored.
• Load the entire 2.5 mg of the solution, undiluted, into the approved nebulizer device.
• Inhale the dose until the nebulizer chamber is empty.
• Discard any remaining solution after the administration is complete.

Connection to the Overall Use Protocol

The protocol is centered on daily, continuous inhalation of a standardized, undiluted 2.5 mg dose. This structure is intended to maintain consistency in drug delivery via approved nebulizer systems, which is important for proper administration. The instruction to use the solution undiluted and not to mix it prevents variations in the administration environment. The regimen is defined as an ongoing daily commitment, with specific steps for handling a missed dose.

Research evidence / Overview of studies for Пульмозим (Dornase Alfa)

Evidence for Use in Supporting Pulmonary Function in Cystic Fibrosis

The core research examining Dornase alfa for cystic fibrosis (CF) involved short- to intermediate-term controlled trials. These studies were designed to explore how lung capacity measurements were observed to evolve during the study periods, with a primary focus on specific measurements like Forced Expiratory Volume in 1 second ( FEV1). The research was primarily based on placebo-controlled Randomized Controlled Trials (RCTs). The study populations primarily focused on adult patients and children generally aged 5 years and older.

Studies monitored how these lung function values changed during the observed periods. Studies reported measurements of FEV1 that were observed to be, on average, higher in the group receiving Dornase alfa when compared against the control group. Research highlights changes measured during the study period, primarily over the course of several months.

However, the evidence is limited, and key questions remain. The long-term implications of the observed short-term changes in FEV1 are not fully established by the existing randomized data. Comparative evidence is lacking, meaning there is limited information from studies that directly compare Dornase alfa against other commonly used treatments, such as hypertonic saline, in relation to pulmonary function outcomes.

Evidence Regarding the Reduction of Respiratory Exacerbations

Studies explored outcomes related to episodes of heightened symptom activity, specifically focusing on respiratory exacerbations. This research primarily involved intermediate-term placebo-controlled RCTs, often following patients for six months up to two years. The main outcomes monitored were outcomes describing episodic or acute changes, such as the number of exacerbation events and the time elapsed before a patient required systemic or intravenous antibiotics.

Trials reported patterns related to the frequency of these acute episodes, noting that the total number of exacerbation events measured was numerically lower in the group receiving Dornase alfa when compared to the placebo group. The results apply only to the specific populations studied, and certainty remains low in certain areas. For patients with more advanced or severe lung conditions, the evidence is insufficient to draw firm conclusions.

Known Limitations and Areas of Research Uncertainty

Follow-up durations were limited in the most rigorous controlled trials when considering the long-term, progressive nature of CF. Consequently, there is limited information for long-term outcomes regarding the medication’s influence on the overall progression of lung disease. The lack of comparative evidence means that information describing Dornase alfa relative to other treatments is not available across the broader evidence landscape. Subgroup findings are uncertain, especially concerning patients with severe disease or the very youngest children.

Common questions about Пульмозим (FAQ)

Q: Is Pulmozyme an antibiotic or not?

A: No, this medication is not classified as an antibiotic. Official documents classify Pulmozyme as a recombinant human enzyme and a mucolytic agent. It is often used alongside other standard therapies, including antibiotics.

Q: Does Pulmozyme help with cough?

A: The drug’s mechanism is described as breaking down thick secretions, which helps thin the mucus. This change in the mucus's consistency is described as facilitating the body's natural clearance processes, which include the cough mechanism.

Q: How long after starting Pulmozyme can an effect be noticed?

A: Regulatory patient information indicates that some individuals may notice improvement in their lung function measurements within the first week after starting treatment. Clinical research examines the full impact of treatment over longer periods of continuous therapy.

Q: Does this medication need to be used every day?

A: Official regulatory documents indicate that this medication is established as a daily administration protocol. The treatment is considered a continuous, long-term protocol for the management of cystic fibrosis.

Q: What are the most common side effects of Pulmozyme?

A: Based on data from clinical trials, commonly reported adverse reactions include voice alteration (hoarseness), pharyngitis (sore throat), rash, and laryngitis. These effects are documented in the official safety profile.

Q: Is it true that Pulmozyme causes voice changes?

A: Yes, voice alteration (hoarseness) is a documented and frequently reported adverse reaction associated with the use of the medicine. It is typically considered a common and temporary effect.

Q: What should be done if throat discomfort occurs during Pulmozyme inhalation?

A: Throat discomfort (pharyngitis) is a documented potential side effect of the medicine. Official regulatory patient information suggests contacting a healthcare provider if side effects are severe, worsen, or persist.

Q: Can Pulmozyme affect the results of a sputum analysis?

A: The product functions by breaking down extracellular DNA (eDNA), which is a key component of thick sputum. This action makes the sputum thinner, which is the physical effect of the drug on lung secretions.

Q: Is there dependence on Pulmozyme with long-term use?

A: Official classification indicates that the medication is not a controlled substance. Dependence or abuse potential is not a documented concern in the official labeling for this drug.

Q: What is the mucolytic effect of Pulmozyme?

A: The mucolytic effect is the ability of the drug to reduce the thickness and stickiness (viscoelasticity) of the lung secretions. This is achieved through the enzyme's specific action of breaking down the extracellular DNA in the mucus.

Q: For which specific lung diseases is Pulmozyme intended?

A: The product is specifically indicated for use in the management of patients with cystic fibrosis (CF). The official labeling does not specify use for other lung diseases.

Q: If I am pregnant, can Pulmozyme be used?

A: The safety profile for the medication has not been established in studies specific to pregnant women. Official documents indicate that caution should be exercised when considering its use during pregnancy.

Q: Does Pulmozyme affect the ability to drive a car?

A: Official regulatory documents state that no effects on the patient's ability to drive vehicles or operate machinery have been reported or documented in regulatory studies.

Q: Why does a runny or stuffy nose sometimes appear during treatment?

A: Symptoms such as a runny or stuffy nose (rhinitis) are listed in the official prescribing information as an adverse reaction reported during clinical trials.

Q: Is Pulmozyme a hormonal drug?

A: No. The medication is classified as a recombinant human enzyme known as deoxyribonuclease I, and it acts as a mucolytic agent. It does not belong to the class of hormonal drugs.

Q: Are there side effects that disappear over time?

A: Yes. Documented safety patterns indicate that adverse reactions are typically mild and transient in nature. The official safety profile notes that the overall incidence of side effects is observed to decrease over time after treatment initiation.

Q: How does Pulmozyme interact with vitamins and dietary supplements?

A: Official regulatory documents state that this medicine can be safely used alongside standard therapies for cystic fibrosis. This includes compatibility with both vitamins and pancreatic enzyme supplements.

Q: How long does a course of Pulmozyme treatment usually last?

A: Treatment is established in regulatory documents as a continuous, long-term daily protocol for the management of cystic fibrosis. It is typically not administered as a short course.

Q: Can Pulmozyme interact with alcohol?

A: Official labeling and interaction studies do not document clinically relevant systemic interactions with alcohol.

Q: Is there a risk of overdose when using Pulmozyme?

A: The official label suggests that if accidental exposure to a dose higher than prescribed occurs, immediate medical attention should be sought.

Q: In what forms, other than inhalation solution, is Pulmozyme released?

A: The medication is supplied solely as a sterile, clear, colorless aqueous solution for inhalation, packaged in single-dose ampules. No other forms of release are officially noted in regulatory documents.

Q: How does Pulmozyme differ from other sputum-thinning medications?

A: This drug differs because its unique mechanism of action is to specifically break down extracellular DNA (eDNA) in the mucus. This enzymatic action targets a key structural component that contributes to the abnormal thickness of secretions in cystic fibrosis.

Q: Does the inhaler need to be cleaned immediately after using Pulmozyme?

A: Patients are instructed to follow the specific manufacturer's instruction manual for the nebulizer device regarding its use, maintenance, and cleaning procedures. Specific cleaning protocols are determined by the device used.

Q: Can Pulmozyme be used if I have heart problems?

A: Official regulatory documents list known hypersensitivity to the drug as the only absolute contraindication. There are no specific contraindications or warnings related to heart problems mentioned in the official prescribing information.

Storage and Disposal Requirements for Pulmozyme (Dornase Alfa)

Pulmozyme inhalation solution requires strict environmental control to maintain the stability of the enzyme. The medicine must be stored refrigerated between 2 C to 8 C (36 F to 46 F) and must be protected from freezing.

Handling and Protection

Keep the ampules in the original protective foil pouch and outer carton to shield the solution from light and excessive heat. Ampules are for single-use only; any unused solution must be immediately discarded after opening. The product must be kept out of the sight and reach of children.

Disposal

Unused or expired Pulmozyme must not be disposed of in wastewater or household trash, and should be returned to a pharmacy or local collection scheme.